Basal bolus versus basal plus correction insulin regimen for the management of medical and surgical patients with type 2 diabetes
Source: Diabetes Care
Area: News
According to the results of a prospective, multicentre, open-label study published early online in Diabetes Care, the use of a 'basal plus' regimen of insulin (glargine once daily plus corrective doses of glulisine insulin before meals) in the management of general medical and surgical patients with type 2 diabetes results in similar glycaemic control to a standard basal bolus regimen. According to the authors, recent randomised trials have shown that use of a basal bolus insulin regimen for patients with type 2 diabetes who are admitted to general medicine and surgery wards results in lower mean daily blood glucose and in a higher percentage of blood glucose readings within target range than treatment with sliding scale insulin (SSI). Clinical practice guidelines therefore recommend this as the preferred approach; however it has not been adopted by all, possibly due to concerns of its complexity and the fear of hypoglycaemia.
The authors of the current study ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news
More News: Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Insulin | Lantus | Study